Skip to main content
Toggle navigation
Search
Home
Back
Favorite
0
Like
Facebook
Tweet
Print
SESSION 4: TRIPLE NEGATIVE BREAST CANCER
Novel ADCs – Saci, TDXd, dato-DXD, HER-3DXD, LIV-1 & Others
Thursday, April 28, 2022
9:25 AM – 9:45 AM
Speaker(s)
Komal Jhaveri, MD, FACP
Memorial Sloan Kettering Cancer Center
New York, New York
Learning Objectives:
Evaluate the mechanisms, safety, and efficacy data of newer and emerging agents in the treatment of TNBC
Discuss monitoring and managing treatment-related adverse effects in the setting of TNBC